United StatesÚltimas notícias

When Block laid off nearly half its staff last week, co-founder Jack Dorsey offered a seemingly simple explanation: artificial intelligence was allowing the company to do more with fewer employees. The announcement, though, landed at the center of a complex debate over AI and the future of work: on one side, genuine fear that the technology will displace jobs at an unprecedented pace; on the other, deep cynicism that companies are exploiting that fear to dress up old-fashioned cost-cutting as technological futurism. Marcelo P. Lima, Founder and Managing Partner at Heller House, joins Bloomberg Businessweek Daily to discuss. Lima has been a vocal critic of Dorsey's management style at Block, and posted soon after the layoff announcement that the reduction in force "is the new Citrini fake narrative." Lima speaks with Carol Massar and Tim Stenovec.

BNY Chief Commercial Officer Cathinka Wahlstrom and Chief Product and Innovation Officer Carolyn Weinberg sat down with Romaine Bostick to discuss AI's role in client onboarding, traditional & digital finance, and the potential of blockchain and digital assets. (CORRECT: Updated title of guest in description)

Defense stocks surged Monday as military attacks escalated across the Middle East, with operations in the region underscoring that air and naval assets remain central to military strategy, which is likely to support the proposed US $1.5 trillion defense funding request. The group has rallied over the past year as global tensions intensified following the conflict between Russia and Ukraine, the US ouster of Venezuelan President Nicolás Maduro, and President Donald Trump's threats about taking over Greenland, which further fueled the rush into defense stocks. Bloomberg Intelligence Senior Defense Analyst Wayne Sanders joins Bloomberg Businessweek Daily to discuss. He speaks with Carol Massar and Tim Stenovec.

Inflation is re-emerging as the crucial worry in the $30 trillion Treasuries market as investors see the risk of a protracted conflict in the Mideast that keeps crude prices elevated. For weeks, haven buying was the dominant driver of US government bonds. Treasuries just logged their best month in a year as investors sought shelter from losses in stocks and fretted about mounting tensions between the US and Iran. But on Monday, that flight-to-safety trade evaporated abruptly as the breakout of war in the Middle East over the weekend triggered a surge in oil prices. Michael Contopoulos, Deputy CIO at Richard Bernstein Advisors, joins Bloomberg Businessweek Daily to discuss. He speaks with Carol Massar and Tim Stenovec.

David Sharp, director of ETF capital markets at Vanguard, talks with Katie Greifeld and Eric Balchunas on "Bloomberg ETF IQ."

US-Israeli strikes on Iran quickly reverberated across the Middle East. President Donald Trump called on the nation's leaders to capitulate, while the Islamic Republic's security chief ruled out negotiations. Amid these tensions, Sylvia Jablonski, CEO & CIO of Defiance ETFs, talks with Katie Greifeld and Eric Balchunas on "Bloomberg ETF IQ." They discuss the Defiance Drone And Modern Warfare ETF (ticker: JEDI).

Breakwave Tanker Shipping ETF (ticker: BWET) is soaring in Monday's trading session. Rising oil-shipping costs amid the conflict in Iran is driving the rally. The ETF is currently the world's best-performing non-leveraged ETF with year-to-date returns nearing 200%. On "Bloomberg ETF IQ," Katie Greifeld and Eric Balchunas report.

Precision BioSciences (NASDAQ:DTIL) announced Monday that it has achieved a $7.5 million clinical milestone under its licensing agreement with TG Therapeutics (NASDAQ:TGTX).

GT Biopharma (NASDAQ:GTBP) reported fiscal 2025 results on Monday, detailing a significant pivot toward its advanced camelid nanobody platform.

Astrana Health (NASDAQ:ASTH) delivered a year of explosive scale in 2025, according to financial results released Monday, with total revenue reaching $3.18 billion.

AAON (NASDAQ:AAON) reported fourth-quarter net income of $32 million on Monday, falling short of Wall Street expectations as the company absorbed significant costs related to its rapid capacity expansion.

Takeda (NYSE:TAK) and Protagonist Therapeutics (NASDAQ:PTGX) secured a major regulatory milestone on Monday as the U.S. Food and Drug Administration (FDA) granted Priority Review to rusfertide, an investigational treatment for polycythemia vera (PV).